RBC Capital raised the firm’s price target on Axsome Therapeutics (AXSM) to $140 from $138 and keeps an Outperform rating on the shares as part ...

Needham analyst Ami Fadia maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of $133.00.Don't ...

M&A didn’t return as hoped for in 2024. The biopharma industry is heading into the J.P. Morgan Healthcare Conference next ...

Among significant news in a holiday spattered week, Dutch biotech argenx gained another approval in Japan for its Vyvdura ...

The company recently announced results from two Phase 3 trials of AXS-05 for agitation. ACCORD-2, hit its main goal, but ...

With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...

Axsome Therapeutics Inc (AXSM) stock saw a decline, ending the day at $84.78 which represents a decrease of $-1.92 or -2.21% from the prior close of $86.7. The stock opened at $82 and touched a low of ...

Axsome Therapeutics shows strong revenue growth with promising pipeline drugs for migraine, fibromyalgia, and narcolepsy.

US CNS specialist Axsome Therapeutics yesterday announced the completion of its Phase III clinical program evaluating AXS-05 ...

On Monday, Axsome Therapeutics, Inc. (NASDAQ:AXSM) released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 ...

Needham & Company LLC reiterated their buy rating on shares of Axsome Therapeutics (NASDAQ:AXSM – Free Report) in a research ...

Axsome Therapeutics (AXSM) is down more than -6% after announcing an advanced-2 Phase 3 trial for its AXS-05 Alzheimer’s disease treatment did not demonstrate statistical significance for the primary ...